Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Lantheus Holdings, Inc. due to misleading statements regarding the competitive position of its product Pylarify, which led to significant financial losses for investors [4][6]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Lantheus between February 26, 2025, and August 5, 2025, to discuss their legal options [1][4]. - There is a deadline of November 10, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Lantheus [4]. Group 2: Financial Performance and Impact - Lantheus reported disappointing first-quarter results on May 7, 2025, with Pylarify's performance falling short of market expectations [7]. - On August 6, 2025, Lantheus announced further disappointing results, reducing growth expectations for Pylarify, which had declined by 8.3% year-over-year, and slashed fiscal year 2025 growth projections [7]. - Following these announcements, Lantheus' stock price plummeted from $72.83 per share on August 5, 2025, to $51.87 per share on August 6, 2025, marking a decline of approximately 28.8% in one day [8]. Group 3: Investor Actions - Investors and analysts reacted swiftly to the negative revelations about Lantheus, leading to a significant drop in the company's stock price [8]. - The lead plaintiff in a class action is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [9].

Core Viewpoint - The Lantheus Holdings, Inc. class action lawsuit alleges that the company and its executives misled investors regarding the company's revenue outlook and growth potential, particularly concerning its key product, Pylarify, which is used in prostate cancer diagnosis and treatment [1][3]. Group 1: Allegations and Financial Impact - The lawsuit claims that Lantheus created a false impression of having reliable information about its projected revenue and growth while downplaying risks from competition and market dynamics [3]. - On May 7, 2025, Lantheus reported a year-over-year decrease in Pylarify sales and reduced its full-year growth projections from low-single-digit to mid-single-digit growth to flat-to-low single-digit growth, resulting in a stock price drop of over 23% [4]. - On August 6, 2025, Lantheus announced further disappointing results, with Pylarify sales down 8.3% year-over-year, leading to a nearly 29% decline in stock price after slashing fiscal year 2025 growth projections [5]. Group 2: Legal Process and Representation - Investors who purchased Lantheus securities during the class period (February 26, 2025, to August 5, 2025) can seek appointment as lead plaintiff in the class action lawsuit, which allows them to act on behalf of other class members [6]. - The lead plaintiff can choose a law firm to represent the class, and participation as lead plaintiff does not affect an investor's ability to share in any potential recovery [6]. Group 3: Company Overview - Lantheus develops, manufactures, and commercializes diagnostic and therapeutic products for heart, cancer, and other diseases, with Pylarify being a key product in its portfolio [2].

Core Viewpoint - A securities class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly making false and misleading statements regarding its product PYLARIFY and its competitive position during the specified class period from February 26, 2025, to August 5, 2025 [1][2]. Allegations of Misconduct - The lawsuit claims that Lantheus misled investors about PYLARIFY's competitive position, failing to properly assess pricing and competitive dynamics [2]. - It is alleged that Lantheus did not disclose that a price increase in early 2025, despite previous price erosion, created opportunities for competitive pricing, jeopardizing PYLARIFY's price point and revenue potential [2]. - The complaint asserts that the public statements made by Lantheus were materially false and misleading throughout the class period [2]. Lead Plaintiff Process - Investors in Lantheus have until November 10, 2025, to seek appointment as a lead plaintiff representative in the class action [3]. - A lead plaintiff acts on behalf of all class members and is typically the investor or group of investors with the largest financial interest [3]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery from the lawsuit [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4]. - The firm encourages Lantheus investors who have suffered losses to contact them for more information [4].

Core Viewpoint - A class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly making materially false and misleading statements regarding its product Pylarify and its competitive position during the class period from February 26, 2025, to August 5, 2025 [3][7]. Allegation Details - The lawsuit claims that Lantheus provided overly positive statements while concealing adverse facts about Pylarify's competitive position [3]. - It is alleged that the company was not adequately equipped to assess pricing and competitive dynamics for Pylarify [3]. - The complaint states that a price increase in early 2025, despite previous price erosion, created opportunities for competitive pricing, jeopardizing Pylarify's price point, revenue, and growth potential [3]. - As a result, the statements made by the defendants regarding the company's business and prospects were materially false and misleading [3]. Next Steps - Investors who purchased Lantheus shares and suffered losses are encouraged to contact the law firm for more information and to discuss their rights [4][7]. - There is no cost or obligation for investors to inquire about their claims [4]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation [5]. - The firm has offices in New York, California, and South Carolina and handles cases in state and federal courts across the country [5].

Core Points - A shareholder has filed a securities class action lawsuit on behalf of investors who purchased or acquired Lantheus Holdings, Inc. securities between February 26, 2025, and August 5, 2025 [1] - The lawsuit alleges that the defendants made misrepresentations regarding the competitive position of Lantheus' key Radiopharmaceutical Oncology product, Pylarify [2] Legal Proceedings - Investors wishing to serve as lead plaintiff must file papers by November 10, 2025, and representation is on a contingency fee basis, meaning shareholders pay no fees or expenses [3] - The law firm Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has been recognized for its success in litigating class actions [4]

Core Viewpoint - A class action securities lawsuit has been filed against Lantheus Holdings, Inc. for alleged securities fraud affecting investors between February 26, 2025, and August 5, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that Lantheus made false statements and concealed information regarding its revenue outlook and growth potential, particularly related to the sales growth of its product Pylarify [2] - Allegations include that Lantheus misrepresented its understanding of market dynamics, including competition, pricing, seasonality, and macroeconomic factors [2] Group 2: Investor Information - Investors who suffered losses during the specified period have until November 10, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Viewpoint - Investors in Lantheus Holdings, Inc. have the opportunity to lead a securities fraud class action lawsuit due to alleged misleading statements regarding the company's market understanding and business prospects [1][2]. Summary by Relevant Sections Lawsuit Details - The lawsuit claims that from February 26, 2025, to August 5, 2025, Lantheus failed to disclose critical information about its understanding of the pricing and competitive dynamics of the Pylarify market [2]. - The complaint asserts that the positive statements made by the defendants regarding the company's business operations and future prospects were materially misleading and lacked a reasonable basis [2]. Participation Information - Investors who suffered losses on their Lantheus investments are encouraged to participate in the lawsuit, with a lead plaintiff deadline set for November 10, 2025 [2]. - Interested parties can contact Glancy Prongay & Murray LLP for more information or to learn about their rights regarding the lawsuit [3][4].

Core Viewpoint - A class action securities lawsuit has been filed against Lantheus Holdings, Inc. for alleged securities fraud affecting investors between February 26, 2025, and August 5, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements and concealed information regarding the company's revenue outlook and growth potential, particularly related to Pylarify's sales growth and market dynamics [2]. - It is alleged that Lantheus did not accurately understand the pricing and competitive dynamics of Pylarify's market, contrary to the optimistic reports provided by the company [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until November 10, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Law Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly making false and misleading statements regarding its market position and product performance, particularly concerning Pylarify [2]. Group 1: Lawsuit Details - The class period for the lawsuit is from February 26, 2025, to August 5, 2025, with a deadline for lead plaintiff appointments set for November 10, 2025 [2]. - The complaint alleges that Lantheus overstated the market leadership of Pylarify while its competitors were gaining market share, leading to significant declines in sales throughout 2025 [2]. Group 2: Shareholder Participation - Shareholders who purchased shares during the class period are encouraged to contact the DJS Law Group for potential lead plaintiff appointments, although this is not required to participate in any recovery [2][3]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case status at no cost [3]. Group 3: Law Firm Background - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [4].

Core Viewpoint - A class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly making materially false and misleading statements regarding its product Pylarify and its competitive position during the specified class period [7]. Allegation Details - The lawsuit claims that Lantheus provided overly positive statements while concealing adverse facts about Pylarify's competitive position [3]. - It is alleged that Lantheus was not adequately equipped to assess pricing and competitive dynamics for Pylarify [3]. - The company reportedly failed to disclose that a price increase in early 2025, despite previous price erosion, created opportunities for competitive pricing, jeopardizing Pylarify's price point and growth potential [3]. - As a result, statements made by the defendants regarding the company's business and prospects were materially false and misleading [3]. Next Steps - Investors who purchased Lantheus shares and suffered losses are encouraged to contact the law firm for more information and to discuss their rights [4]. - There is no cost or obligation for investors to inquire about their claims [4]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is November 10, 2025 [7].